Gilead Sciences Sees FY24 Adj. EPS $6.85-$7.25 Vs $7.21 Est.; Revenue $27.1B-$27.5B Vs $27.663B Est.
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences projects its FY24 adjusted EPS to be between $6.85 and $7.25, compared to the estimated $7.21. The company also forecasts revenue to range from $27.1 billion to $27.5 billion, slightly below the estimated $27.663 billion.
February 06, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead Sciences projects lower-than-expected FY24 adjusted EPS and revenue, indicating potential challenges ahead.
Gilead Sciences' projection of both adjusted EPS and revenue for FY24 falling below analyst estimates suggests potential headwinds for the company. This could lead to negative investor sentiment in the short term, impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100